REG - Trellus Health PLC - Contract Extension with Johnson & Johnson

Trellus HealthAnnouncement

18/02/2026 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260218:nRSR3868Ta&default-theme=true

RNS Number : 3868T  Trellus Health PLC  18 February 2026

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Contract Extension with Johnson & Johnson Health Care Systems

Extension granted due to key engagement and satisfaction metrics achieved

Pharmaceutical verticals continue to scale

 

LONDON, U.K. AND NEW YORK, U.S. (18 February 2026). Trellus Health plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programmes and value-based solutions to manage complex chronic
conditions, announces a six-month contract extension with Johnson &
Johnson Health Care Systems ("J&J") to continue to provide Trellus
Elevate™, supporting patients with moderate to severely active inflammatory
bowel disease ("IBD") who are prescribed a J&J therapy for treatment of
IBD.

 

The collaboration with J&J, initially signed in January 2025
(https://trellus-health-plc.flint-platform.com/regulatory-news/76061) , has
been extended to mid-2026 with the same economic terms, including a fixed
monthly management fee. A key factor in the extension was the achievement of
engagement and satisfaction metrics during the initial pilot phase. Based on
these metrics, J&J broadened the way patients can access the enrolment
channels beyond the initial pilot funnel in mid-January 2026, reflecting
continued confidence in the programme's performance.

 

This extension provides eligible patients prescribed a J&J therapy access
to Trellus Elevate™, offering patients the tools and confidence to navigate
the emotional and physical challenges of their conditions, staying engaged and
adhering to their treatment plans.

 

The Company also continues to move forward with its TrialSet™ vertical,
which is being deployed into agreed-upon sites with ICON plc for an ongoing,
mid-stage immunology and inflammation clinical trial sponsored by Takeda.
Trellus is also implementing TrialSet™ with PSI Inc. across two late-stage
immunology and inflammation clinical trials sponsored by Sanofi and will be
deployed into agreed-upon sites beginning mid-Q2.

 

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said, "The
extension of our collaboration with J&J represents further external
validation of our platform and the engagement outcomes achieved during the
pilot phase. Together with the rollout of TrialSet™ with leading CRO
partners, Trellus Health operates across the full programme lifecycle, from
clinical trials through commercial deployment, using our proprietary
resilience methodology to support engagement and programme success. We are
establishing a scalable go-to-market model for pharma, with continued focus on
disciplined execution, recurring revenue growth and expansion across
immunology and inflammation. We look forward to updating the market on further
developments."

 

Funding and Outlook

As previously disclosed, the Company expects revenue for the year ended 2025
to be c. $545,000 and has further reduced its monthly cash burn to c.$400,000
by late 2025 from c.$440,000 in October 2025. This was moderately offset by
recurring monthly management fees generated during the second half of the
year.

 

As announced previously, the Company has secured a £5 million convertible
facility with Alumni Capital LLC, which was approved by shareholders on 20
January 2026. The net proceeds of the First Tranche Notes and Second Tranche
Notes, (£737,500 in gross principal), are expected to extend the Company's
cash runway into late Q1 2026. The Directors continue ongoing discussions
regarding additional sources of funding to further extend the Company's cash
runway, irrespective of the utilisation of the Notes.

 

The Board remains focused on accelerating commercial momentum by expanding the
Company's footprint through strategic partnerships, deepening pharmaceutical
partnerships and scaling TrialSet™ across additional programmes and
sponsors. The Directors believe the recent contract extension, combined with
ongoing CRO implementations, positions the Company to build increasing
recurring revenue visibility through 2026.

 

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings given to them in the Company's announcement released on 30
December 2025.

 

 

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Phil Davies / James Todd / Patrick Weaver                             Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Lianne Applegarth / Alice Woodings          Mob: +44 (0)7584 391 303 / +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation. Both the
founders continue to have a financial interest in the Company.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTTRMFTMTMBBLF



            Copyright 2019 Regulatory News Service, all rights reserved